Cosentyx unoready 300 MG pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F7NXX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,529
Award facts
- Contract value 100% obligated
- $41,528.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $41,528.84 with a completion date of January 26, 2026, awards Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) a contract for Cosentyx Unoready 300 mg pen 2 mL pharmaceutical supplies. The contract was awarded without set-aside on January 23, 2026, by the Defense Logistics Agency (DLA), with performance at the contractor's Conshohocken, Pennsylvania headquarters. This award represents a firm fixed-price transaction executed under Amerisourcebergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026, which serves as the primary vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune and inflammatory conditions, reflecting the breadth of specialty pharmaceuticals that DLA procures for military medical treatment facilities and veteran healthcare programs. As a major pharmaceutical distributor and critical federal vendor, Amerisourcebergen Drug Corp supplies brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains through competitively awarded contracts. The parent company, Cencora, Inc., also maintains a separate Indefinite Delivery Contract with DLA valued at up to $999,999,999.00 through December 31, 2031, underscoring the company's significant role in the federal pharmaceutical supply chain supporting Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F7NXX?
SPE2DR26F7NXX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26F7NXX worth?
The government has obligated $41,529 on SPE2DR26F7NXX.
Is contract SPE2DR26F7NXX an order under another contract?
Yes. SPE2DR26F7NXX is a delivery order under SPE2DR25D7059, an indefinite delivery contract.
Was contract SPE2DR26F7NXX competed?
The extent of competition for SPE2DR26F7NXX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award